Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2

Abraira, 1998, A critical issue: intensive insulin treatment and macrovascular disease, Diabetes Care, 21, 669, 10.2337/diacare.21.4.669

Abraira, 1995, Results of the feasibility trial, Diabetes Care, 18, 1113, 10.2337/diacare.18.8.1113

Abraira, 1997, Cardiovascular events and correlates in the VA Feasibility Trial (VACSDM), Archives of Internal Medicine, 157, 181, 10.1001/archinte.1997.00440230053007

2002, Consensus statement on guidelines for glycemic control, Endocrine Practice, 8, 5

2000, Clinical practice recommendations 2002, Diabetes Care, 25, S33

Barrett-Connor, 1997, Does hyperglycemia really cause coronary artery heart disease?, Diabetes Care, 20, 1620, 10.2337/diacare.20.10.1620

Camacho, 2000, Beneficial and detrimental effects of intensive glycemic control, with emphasis on type 2 diabetes mellitus, Drugs & Aging, 17, 463, 10.2165/00002512-200017060-00004

Chang, 1998, Evaluation and interference study of hemoglobin A1c measured by turbidometric inhibition immunoassay, American Journal of Clinical Pathology, 109, 274, 10.1093/ajcp/109.3.274

DeClerk, 1988, Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay, Blood, 71, 220, 10.1182/blood.V71.1.220.220

Department of Veterans Affairs, Office of Quality and Performance. Management of diabetes mellitus in primary care [Link: Annotations]. Available at: http://www.oqp.med.va.gov/cpg/DM/dm_cpg/content/ModG/modG_fr.htm. Accessed October 2002.

1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, New England Journal of Medicine, 329, 977, 10.1056/NEJM199309303291401

Duckworth, 2001, The Department of Veterans Affairs Diabetes Trial, Diabetes Care, 24, 942, 10.2337/diacare.24.5.942

Duckworth, 1998, The Veterans Affairs Implantable Insulin Group study: effect on cardiovascular risk factors, Diabetes Care, 21, 1596, 10.2337/diacare.21.10.1596

Eastman, 1997, Model of complications of NIDDM II: analysis of the health benefits and cost effectiveness of treating NIDDM, Diabetes Care, 20, 735, 10.2337/diacare.20.5.735

1992, Aspirin effects on mortality and morbidity in patients with diabetes mellitus: early treatment diabetic retinopathy study report 14, JAMA, Journal of the American Medical Association, 268, 1292, 10.1001/jama.1992.03490100090033

Ferris, 1993, How effective are treatments for diabetic retinopathy?, JAMA, Journal of the American Medical Association, 269, 1290, 10.1001/jama.1993.03500100088034

Geiss, 1995, Mortality in non-insulin-dependent diabetes, 133

Gold, 1995, Hypoglycemia-induced cognitive dysfunction in diabetes mellitus: effect of hypoglycemia unawareness, Physiology & Behavior, 58, 501, 10.1016/0031-9384(95)00085-W

Gold, 1997, Hypoglycaemia and non-cognitive aspects of psychological function in insulin-dependent (type 1) diabetes mellitus (IDDM), Diabetic Medicine, 14, 111, 10.1002/(SICI)1096-9136(199702)14:2<111::AID-DIA309>3.0.CO;2-S

Kannel, 1990, Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience, American Heart Journal, 120, 672, 10.1016/0002-8703(90)90026-T

Klein, 1995, Vision disorders in diabetes, 293

Laakso, 1999, Hyperglycemia and cardiovascular disease in type 2 diabetes, Diabetes Care, 48, 937, 10.2337/diabetes.48.5.937

Levin, 2000, The effect of intensive glycemic control on microalbuminuria in type 2 diabetes mellitus, Diabetes Care, 23, 1478, 10.2337/diacare.23.10.1478

Lezak, 1995, Orientation and attention, 357

Meigs, 1997, Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM patient outcomes research team, American Journal of Medicine, 102, 38, 10.1016/S0002-9343(96)00383-X

National Committee for Quality Assurance & American Diabetes Association. Diabetes Physician Recognition Program. Available at: http://www.ncqa.org/dprp. Accessed October 2002.

Pyorala, 1997, Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S), Diabetes Care, 20, 614, 10.2337/diacare.20.4.614

Sacks, 1996, Cholesterol and recurrent events trial investigators: the effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, New England Journal of Medicine, 335, 1001, 10.1056/NEJM199610033351401

Shichiri, 2000, Long term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients, Diabetes Care, 23, B21

Stratton, 2000, Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, British Medical Journal, 321, 405, 10.1136/bmj.321.7258.405

Swaim, 1967, Fibrinogen assay, Clinical Chemistry, 13, 1026, 10.1093/clinchem/13.11.1026

Turner, 1996, The effect of improved metabolic control on complications of NIDDM: UKPDS 17, Annals of Internal Medicine, 124, 136, 10.7326/0003-4819-124-1_Part_2-199601011-00011

1998, Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risks of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6

1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ, British Medical Journal, 317, 703, 10.1136/bmj.317.7160.703

Vijan, 1997, Estimated benefits of glycemic control in microvascular complications in type 2 diabetes, Annals of Internal Medicine, 127, 788, 10.7326/0003-4819-127-9-199711010-00003

von Clauss, 1957, Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens, Acta Haematologica, 17, 237, 10.1159/000205234

Zhang, 2000, Performance status of health care facilities changes with risk adjustment of HbA1c, Diabetes Care, 23, 919, 10.2337/diacare.23.7.919